Aflibercept Injection [Eylea]
Aflibercept Injection [Eylea] is a pharmaceutical drug with 16 clinical trials. Currently 2 active trials ongoing. Historical success rate of 90.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
0
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
90.0%
9 of 10 finished
10.0%
1 ended early
2
trials recruiting
16
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Mean Visual Acuity Changes Following Five Injections of Aflibercept
Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity
Clinical Trials (16)
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Mean Visual Acuity Changes Following Five Injections of Aflibercept
Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
Maximum Treatment Interval With Aflibercept T&E
Navigated Laser In Branch Retinal Vein Occlusion Study
Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage
One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab
Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME
Effect Aflibercept on Ocular Perfusion
Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection
Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3
All 16 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 16